A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease

Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β-amyloid (1–42) in human cerebrospinal fluid

(2016) Tobias Bittner et al.   Alzheimers & Dementia

CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis

(2016) Bob Olsson et al.   LANCET NEUROLOGY

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

(2016) Jeff Sevigny et al.   NATURE

Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials

(2016) Rik Vandenberghe et al.   Alzheimers Research & Therapy

Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease

(2015) Hlin Kvartsberg et al.   Alzheimers & Dementia

Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease

(2015) Maartje I. Kester et al.   JAMA Neurology

Neurogranin Levels in Cerebrospinal Fluid

(2015) Henrik Zetterberg et al.   JAMA Neurology

Targeting Prodromal Alzheimer Disease With Avagacestat

(2015) Vladimir Coric et al.   JAMA Neurology

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

(2014) Stephen Salloway et al.   NEW ENGLAND JOURNAL OF MEDICINE

An MRI Rating Scale for Amyloid-Related Imaging Abnormalities with Edema or Effusion

(2013) F. Barkhof et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

Rationale for use of the Clinical Dementia Rating Sum of Boxes as a primary outcome measure for Alzheimer’s disease clinical trials

(2012) Jesse M. Cedarbaum et al.   Alzheimers & Dementia

Progression of Alzheimer’s disease as measured by Clinical Dementia Rating Sum of Boxes scores

(2012) Monique M. Williams et al.   Alzheimers & Dementia

Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease

(2012) Randall J. Bateman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Suitability of the Clinical Dementia Rating-Sum of Boxes as a single primary endpoint for Alzheimer’s disease trials

(2011) Nicola Coley et al.   Alzheimers & Dementia

Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Reisa A. Sperling et al.   Alzheimers & Dementia

Using Positron Emission Tomography and Florbetapir F 18 to Image Cortical Amyloid in Patients With Mild Cognitive Impairment or Dementia Due to Alzheimer Disease

(2011) Adam S. Fleisher   ARCHIVES OF NEUROLOGY

Mechanism of Amyloid Removal in Patients With Alzheimer Disease Treated With Gantenerumab

(2011) Susanne Ostrowitzki   ARCHIVES OF NEUROLOGY

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

(2010) Kaj Blennow et al.   Nature Reviews Neurology

Robust atrophy rate measurement in Alzheimer's disease using multi-site serial MRI: Tissue-specific intensity normalization and parameter selection

(2009) Kelvin K. Leung et al.   NEUROIMAGE

Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism

(2008) Christopher C Rowe et al.   LANCET NEUROLOGY